{"id":3911,"date":"2024-07-01T11:00:35","date_gmt":"2024-07-01T02:00:35","guid":{"rendered":"https:\/\/www.nanomrna.co.jp\/en\/?page_id=7"},"modified":"2026-06-18T13:22:36","modified_gmt":"2026-06-18T04:22:36","slug":"company","status":"publish","type":"page","link":"https:\/\/www.nanomrna.co.jp\/en\/company\/","title":{"rendered":"About NANO MRNA"},"content":{"rendered":"
\n

NANO MRNA<\/span> is evolving a cycle of mRNA medicine<\/span> IP generation-licensing<\/span> as a platform company that connects drug discovery seeds with medical and drug development needs.<\/p>\n<\/div>\n

<\/div>\n
\n

Corporate Profile<\/h2>\n\n\n\n\n\n\n\n\n\n\n
Corporate Nam<\/th>\nNANO MRNA Co.,Ltd.<\/td>\n<\/tr>\n
Location<\/th>\n\n
\n
Office<\/h5>\n

6F NOVEL WORK Kanda, 2-10-4 Kanda Tsukasamachi, Chiyoda-ku, Tokyo 101-0048, Japan

\nTEL: +81 (0)3-3527-1828
FAX: +81 (0)3-3527-1827<\/p>\n

Map<\/a><\/div>\n<\/div>\n
Subsidiary Company<\/th>\nPrimRNA Co., Ltd.<\/a><\/td>\n<\/tr>\n
Luna RD co., ltd.<\/a><\/td>\n<\/tr>\n
Establishment<\/th>\nApril 1, 2026<\/td>\n<\/tr>\n
Capital<\/th>\nJPY 90 million (As of April 1, 2026)<\/td>\n<\/tr>\n
Director<\/th>\n\n

President & Representative Director<\/span>Shiro Akinaga<\/span><\/p>\n

Director<\/span>Daisuke Nakashima<\/span><\/p>\n

Director<\/span>Norihiko Shiraishi<\/span><\/p>\n

Director<\/span>Nobuhiro Todokoro<\/span><\/p>\n

Corporate Auditor<\/span>Seiichiro Wada<\/span><\/p>\n<\/td>\n<\/tr>\n

Scopes of Business<\/th>\nR&D and production of pharmaceuticals using micellar nanoparticles technology.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n
\n
\n
<\/figure>\n

History<\/p>\n

<\/a>\n<\/div>\n<\/div>\n

\n
\n
<\/figure>\n

Access<\/p>\n

<\/a>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NANO MRNA is evolving a cycle of mRNA medicine IP generation-licensing as a platform company that connects dru […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":10,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-3911","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/3911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/comments?post=3911"}],"version-history":[{"count":86,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/3911\/revisions"}],"predecessor-version":[{"id":4694,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/3911\/revisions\/4694"}],"wp:attachment":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/media?parent=3911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}